Abstract
Professor Bae is Associate Editor for the Americas and an Editor of concept papers for the Journal of Controlled Release. He also serves several journals as a member of their editorial boards. His research interests include the rational design of carriers for small-molecule anticancer drugs, genetic materials and proteins, and multifunctional nanotechnology to overcome tumor heterogeneity and multidrug resistance. He is also interested in developing novel preclinical models with increased predictive power. Professor Bae discusses ‘passive‘ and ‘active‘ targeting approaches to nanoparticle oncology research with Laura Harvey (Commissioning Editor) at Therapeutic Delivery.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.